Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

Posted: August 5, 2022 at 2:03 am

MONT-SAINT-GUIBERT, Belgium, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced an update on its financial results and recent business developments for the first half ended June 30, 2022.

Follow this link:
Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

Related Posts